AU618085B2 - Occlusive body for administering a physiologically active substance - Google Patents

Occlusive body for administering a physiologically active substance Download PDF

Info

Publication number
AU618085B2
AU618085B2 AU32895/89A AU3289589A AU618085B2 AU 618085 B2 AU618085 B2 AU 618085B2 AU 32895/89 A AU32895/89 A AU 32895/89A AU 3289589 A AU3289589 A AU 3289589A AU 618085 B2 AU618085 B2 AU 618085B2
Authority
AU
Australia
Prior art keywords
membrane
active substance
physiologically active
cavity
occlusive body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32895/89A
Other languages
English (en)
Other versions
AU3289589A (en
Inventor
John Mark Tucker
Mark Rupert Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3289589A publication Critical patent/AU3289589A/en
Application granted granted Critical
Publication of AU618085B2 publication Critical patent/AU618085B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
AU32895/89A 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance Ceased AU618085B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8804164 1988-02-23
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound

Publications (2)

Publication Number Publication Date
AU3289589A AU3289589A (en) 1989-09-22
AU618085B2 true AU618085B2 (en) 1991-12-12

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32895/89A Ceased AU618085B2 (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Country Status (11)

Country Link
US (1) US5254346A (OSRAM)
EP (2) EP0336543A1 (OSRAM)
JP (1) JP2716231B2 (OSRAM)
KR (1) KR970009723B1 (OSRAM)
AU (1) AU618085B2 (OSRAM)
DE (1) DE68915291T2 (OSRAM)
ES (1) ES2052071T3 (OSRAM)
GB (1) GB8804164D0 (OSRAM)
IN (1) IN172748B (OSRAM)
WO (1) WO1989007959A1 (OSRAM)
ZA (1) ZA891403B (OSRAM)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
EP0470007B1 (en) * 1990-08-03 1995-03-15 Terumo Kabushiki Kaisha Wound-covering materials
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE9219105U1 (de) * 1992-10-31 1998-03-05 Klocke Verpackungs-Service GmbH, 76356 Weingarten Behälter zur Aufnahme von aromatischen Substanzen
EP0668759B1 (en) * 1992-11-09 2003-05-28 Neurogesx, Inc. Transdermal delivery of ketorolac
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
CA2183083C (en) * 1994-03-07 2006-01-03 Charles D. Ebert Drug-containing adhesive composite transdermal delivery device
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) * 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) * 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US6803420B2 (en) 2001-05-01 2004-10-12 Corium International Two-phase, water-absorbent bioadhesive composition
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
RU2276998C2 (ru) 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Гидрогелевые композиции
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7388076B2 (en) * 2002-07-16 2008-06-17 University Of South Florida Human immunosuppressive protein
EP2316459B1 (en) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2729967C (en) * 2002-12-13 2018-01-16 Schering-Plough Healthcare Products, Inc. Use of a transdermal or transmucosal ingredient delivery device
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
EP1620112A4 (en) * 2003-04-17 2007-04-25 Univ Columbia DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
CA2530996C (en) 2003-07-03 2013-05-07 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
WO2005013996A2 (en) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
AU2004269986A1 (en) * 2003-09-08 2005-03-17 Pfizer Consumer Healthcare Health Ab Nicotine formulations and use thereof
CA2554649C (en) 2004-01-30 2015-10-27 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
CA2557532A1 (en) * 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
AU2005271259B2 (en) 2004-08-05 2012-01-19 A.V. Topchiev Institute Of Petrochemical Synthesis Adhesive composition
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1965777A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Transdermal tobacco alkaloid patch
WO2007065428A1 (en) * 2005-12-08 2007-06-14 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
EP2007877B1 (en) * 2006-02-28 2013-04-17 The Trustees of Columbia University in the City of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
RS54764B1 (sr) 2006-07-21 2016-10-31 Biodelivery Sciences Int Inc Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
BRPI0721705A2 (pt) * 2007-05-31 2013-02-13 Fertin Pharma As adesivo reservatàrio transdÉrmico de alcaloide de tabaco
WO2009027850A2 (en) * 2007-06-06 2009-03-05 Multi-Tech Specialty Chemicals Co., Ltd. Process for the preparation of xanthophyll crystals
CA2694325C (en) 2007-07-30 2015-09-22 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
KR101630217B1 (ko) 2008-08-22 2016-06-14 사노피 비만세포 트립타제의 억제제로서 ［４－（５－아미노메틸－２－플루오로-페닐）－피페리딘－１－일］－［7－플루오로－1－(２－메톡시－에틸)－４－트리플루오로메톡시－１ｈ－인돌－３－일］－메타논
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
WO2010085684A1 (en) 2009-01-23 2010-07-29 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
DK2451796T3 (da) 2009-07-08 2013-07-29 Dermira Canada Inc Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
WO2011022371A2 (en) * 2009-08-17 2011-02-24 Silipos Inc. Gel product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
WO2011078984A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
MX2012006739A (es) 2009-12-23 2012-06-28 Sanofi Sa Profarmacos de [4 [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il] -(1h-pirrolo-piridin-il)-metanonas y sintesis de estos.
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
EP2560643A1 (en) 2010-04-20 2013-02-27 Institute for OneWorld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
EA024341B1 (ru) 2010-04-24 2016-09-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
ES2880622T3 (es) 2010-07-28 2021-11-25 Rigel Pharmaceuticals Inc Composiciones y procedimientos para la inhibición de la ruta de JAK
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP2638021B1 (en) 2010-11-13 2018-09-26 Innocrin Pharmaceuticals, Inc. 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
BR112013015572A2 (pt) 2010-12-20 2016-09-27 Colgate Palmolive Co composição para cuidado oral de gelatina encapsulada contendo hidrofílico ativo, agente de estruturação hidrofóbico e transportador de óleo
US9169182B2 (en) 2011-02-25 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit FtsZ protein
US20120231069A1 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
WO2012177635A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2721020B1 (en) 2011-06-19 2019-01-23 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
JP2014523880A (ja) 2011-06-23 2014-09-18 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素化合物
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
BR112014005104A2 (pt) 2011-09-02 2017-07-04 Salk Inst For Biological Studi inibidores camkii, ip3r, calcineurin, p38 e mk2/3 para tratar atar distúrbios metabólicos de obesidade
CN107011323A (zh) 2011-12-11 2017-08-04 威尔金制药有限公司 金属酶抑制剂化合物
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP2804858B1 (en) 2012-01-20 2019-12-25 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
EP3459565A1 (en) 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
US20150157509A1 (en) * 2013-12-11 2015-06-11 Oscar Polk Atkinson Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3778644A3 (en) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
AU2016233113B2 (en) 2015-03-19 2020-05-07 Mycovia Pharmaceuticals, Inc. Antifungal compounds and processes for making
JP6994454B2 (ja) 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
CN108347949B (zh) 2015-09-18 2021-08-13 Nqp 1598公司 抗真菌化合物方法
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
AU2016380349B2 (en) 2015-12-30 2020-10-29 Nqp 1598, Ltd. Metalloenzyme inhibitor compounds
JP6960937B2 (ja) 2016-03-08 2021-11-05 リビング プルーフ インコーポレイテッド 長期持続性化粧品組成物
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
EP3478091B1 (en) 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
EP3532465B1 (en) 2016-10-26 2023-03-01 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
ES2939232T3 (es) 2016-10-26 2023-04-20 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CA3055292A1 (en) 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
CA3068305A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
JP7244494B2 (ja) 2017-09-13 2023-03-22 リビング プルーフ インコーポレイテッド 色保護剤組成物
CN111133023B (zh) 2017-09-13 2022-10-18 生活实验公司 持久化妆品组合物
US12029805B2 (en) 2017-11-20 2024-07-09 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2019210121A1 (en) 2018-04-27 2019-10-31 Living Proof, Inc. Long lasting cosmetic compositions
EA202092581A1 (ru) 2018-05-03 2021-04-08 Ригел Фармасьютикалз, Инк. Соединения, ингибирующие rip1, а также способы их получения и применения
MD3788044T2 (ro) 2018-05-03 2023-12-31 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
BR112022001896A2 (pt) 2019-08-14 2022-06-21 Rigel Pharmaceuticals Inc Método para bloquear ou atenuar síndrome de liberação de citocinas
BR112022003564A2 (pt) 2019-08-30 2022-05-17 Rigel Pharmaceuticals Inc Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método
BR112022002581A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Inibidores heterocíclicos de rip1 quinase
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
AU2020378407B2 (en) 2019-11-07 2024-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067961A (en) * 1975-03-19 1978-01-10 The Procter & Gamble Company Controlled release article
GB2174605A (en) * 1985-05-03 1986-11-12 Alza Corp Transdermal drug delivery
EP0208395A1 (en) * 1985-05-16 1987-01-14 Euroceltique S.A. Transdermal delivery system

Also Published As

Publication number Publication date
ZA891403B (en) 1989-11-29
JPH03503636A (ja) 1991-08-15
IN172748B (OSRAM) 1993-11-20
JP2716231B2 (ja) 1998-02-18
EP0508979B1 (en) 1994-05-11
EP0336543A1 (en) 1989-10-11
DE68915291D1 (de) 1994-06-16
EP0508979A1 (en) 1992-10-21
US5254346A (en) 1993-10-19
DE68915291T2 (de) 1994-09-01
WO1989007959A1 (en) 1989-09-08
KR900700153A (ko) 1990-08-11
KR970009723B1 (ko) 1997-06-17
ES2052071T3 (es) 1994-07-01
GB8804164D0 (en) 1988-03-23
AU3289589A (en) 1989-09-22

Similar Documents

Publication Publication Date Title
AU618085B2 (en) Occlusive body for administering a physiologically active substance
US4927687A (en) Sustained release transdermal drug delivery composition
US5273755A (en) Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US4687481A (en) Transdermal drug delivery system
US4624665A (en) Method of transdermal drug delivery
US4834978A (en) Method of transdermal drug delivery
JP4982670B2 (ja) ２種以上の活性物質のためのドラッグデリバリーシステム
CA1333689C (en) Transdermal drug delivery device
US5234690A (en) Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5614212A (en) Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6024975A (en) Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US4743249A (en) Dermal and transdermal patches having a discontinuous pattern adhesive layer
CA2229184C (en) Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US3797494A (en) Bandage for the administration of drug by controlled metering through microporous materials
CA1302824C (en) Device for administering an active agent to the skin or mucosa
CA1270714A (en) Multicompartmentalized dermal and transdermal patches
EP0593746B1 (en) Transdermal drug delivery system
US5273756A (en) Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US4810499A (en) Transdermal drug delivery system and method
FI100456B (fi) Gestodeenia sisältävän vaikuttavan aineen transdermaaliseen antoon tar koitetun välineen käyttö raskauden ehkäisyyn
JPH044295B2 (OSRAM)
CA2091883A1 (en) Transdermal contraceptive formulations, methods and devices
US6074665A (en) Transdermal therapeutic system for administering active agents to the human body via the skin
EP0273004B1 (de) Benutzer-aktivierte Therapeutische Systeme
EP0252459A1 (en) Compartmentalized transdermal delivery system